Cyber Swan Sale

50% Off Elite

Days

Hours

Mins

Sec

Get our most powerful screeners, new charting tools, and the fastest ad-free experience at our best price ever. One last chance.

REGN

Regeneron Pharmaceuticals, Inc

Dec 03 • 10:28AM ET

732.78

-9.22 -1.24 %

Healthcare • Biotechnology • USA • NASD

Today, 9:46 AMMorgan Stanley downgrades Regeneron (REGN) to Equal Weight from Overweight, keeping $767 price target, citing balanced risk/reward pending visibility on pipeline diversification.

Peers: AMGN BIIB GILD VRTX MRNA BMRN INCY EXEL IONS

| Held by: VTI VOO QQQ IVV SPY VTV IBB XLV JEPI COWZ

Scroll to Statements

Index	NDX, S&P 500	P/E	17.54	EPS (ttm)	41.77	Insider Own	3.73%	Shs Outstand	103.50M	Perf Week	-6.93%
Market Cap	77.01B	Forward P/E	17.01	EPS next Y	43.09	Insider Trans	-0.20%	Shs Float	101.18M	Perf Month	14.09%
Enterprise Value	71.27B	PEG	4.15	EPS next Q	10.76	Inst Own	85.42%	Short Float	2.81%	Perf Quarter	29.19%
Income	4.58B	P/S	5.41	EPS this Y	-5.24%	Inst Trans	-0.88%	Short Ratio	2.58	Perf Half Y	51.11%
Sales	14.25B	P/B	2.49	EPS next Y	-0.32%	ROA	11.80%	Short Interest	2.84M	Perf YTD	2.87%
Book/sh	294.00	P/C	9.11	EPS next 5Y	4.23%	ROE	15.19%	52W High	800.99 -8.52%	Perf Year	-2.33%
Cash/sh	80.40	P/FCF	18.24	EPS past 3/5Y	-18.94% 15.74%	ROIC	13.60%	52W Low	476.49 53.79%	Perf 3Y	-1.17%
Dividend Est.	2.97 (0.41%)	EV/EBITDA	16.36	Sales past 3/5Y	-4.04% 16.71%	Gross Margin	81.71%	Volatility	2.69% 3.16%	Perf 5Y	44.16%
Dividend TTM	3.52 (0.48%)	EV/Sales	5.00	EPS Y/Y TTM	0.50%	Oper. Margin	26.88%	ATR (14)	22.02	Perf 10Y	29.13%
Dividend Ex-Date	Nov 20, 2025	Quick Ratio	3.33	Sales Y/Y TTM	2.89%	Profit Margin	32.13%	RSI (14)	59.19	Recom	1.83
Dividend Gr. 3/5Y	- -	Current Ratio	4.06	EPS Q/Q	18.05%	SMA20	2.40%	Beta	0.39	Target Price	775.67
Payout	0.00%	Debt/Eq	0.09	Sales Q/Q	0.90%	SMA50	14.44%	Rel Volume	0.83	Prev Close	742.00
Employees	15106	LT Debt/Eq	0.09	Earnings	Oct 28 BMO	SMA200	22.39%	Avg Volume	1.10M	Price	732.78
IPO	Apr 02, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.53% 4.51%	Trades		Volume	175,626	Change	-1.24%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$767
Nov-24-25	Resumed	Truist	Buy	$798
Nov-24-25	Initiated	HSBC Securities	Buy	$255
Nov-13-25	Initiated	Scotiabank	Sector Perform	$650
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy	$890
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$580
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$662
May-14-25	Upgrade	Citigroup	Neutral → Buy	$700
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$695
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform	$762 → $834
Jan-16-25	Downgrade	UBS	Buy → Neutral	$1130 → $738
Dec-10-24	Resumed	BofA Securities	Underperform	$565
Nov-15-24	Initiated	Wolfe Research	Outperform	$1150
Nov-14-24	Initiated	Citigroup	Neutral	$895
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform	$1175 → $1077
Mar-12-24	Initiated	Bernstein	Outperform	$1125
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$884 → $1076
Nov-09-23	Initiated	Deutsche Bank	Hold	$800
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform	$950

Show Previous Ratings

Today 09:35AM	Oracle initiated, Uber upgraded: Wall Street's top analyst calls (The Fly)
09:15AM	Here Are Wednesdays Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendys and More (24/7 Wall St.)
Dec-02-25 02:21PM	REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD (Zacks)
09:48AM	Stock Market Today: Nasdaq Rises As AI Stocks Nvidia, Palantir, Astera Rally (Live Coverage) (Investor's Business Daily)
Dec-01-25 12:49PM	Regeneron and Tessera join forces to forge in vivo AATD gene therapy (Pharmaceutical Technology)
10:51AM	Loading…
10:51AM	5 Healthcare Names to Watch as Sector Rotation Is in Full Swing (MarketBeat)
09:48AM	REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? (Zacks)
07:00AM	Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
06:54AM	Regeneron inks gene editing deal with startup Tessera (BioPharma Dive)
Nov-30-25 11:15PM	Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? (Motley Fool)
Nov-28-25 09:59AM	Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? (Zacks)
07:11AM	Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500? (Barchart)
Nov-27-25 11:30AM	Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue? (Zacks)
08:15AM	BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? (Zacks)
Nov-26-25 01:37PM	Dupixent gains chronic spontaneous urticaria indication in Europe (Pharmaceutical Technology)
05:30AM	Loading…
05:30AM	Hedge Funds Pile Into Health Stocks Leading Market in Rotation (Bloomberg)
Nov-25-25 10:45AM	SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria (Zacks)
01:00AM	Dupixent (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) (GlobeNewswire)
Nov-24-25 04:11PM	Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer (Investor's Business Daily)
07:58AM	1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month (Motley Fool)
Nov-23-25 02:51PM	Jim Cramer Says He "Should Have Been Recommending Regeneron" (Insider Monkey)
Nov-22-25 08:30AM	This Medicare premium just crossed $200 a month for the first time. Heres why. (MarketWatch)
Nov-21-25 10:19AM	NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
10:15AM	This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead (Investopedia)
09:06AM	Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth (Zacks)
08:52AM	Are Wall Street Analysts Bullish on Regeneron Pharmaceuticals Stock? (Barchart)
Nov-20-25 05:05PM	Stocks to Watch Thursday Recap: Walmart, Nvidia, Cracker Barrel, Regeneron (The Wall Street Journal)
01:36PM	Stocks to Watch Thursday: Walmart, Nvidia, Cracker Barrel, Regeneron (The Wall Street Journal)
11:08AM	Stock Market Today: Nasdaq, S&P 500 Stage Modest Comeback After Post-Earnings Nvidia Decline (TheStreet)
09:19AM	REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD (Zacks)
07:25AM	Loading…
07:25AM	Regenerons Eylea franchise boosted by pair of FDA approvals (Pharmaceutical Technology)
06:36AM	With new approvals, Regenerons higher-dose Eylea gets more competitive (BioPharma Dive)
Nov-19-25 04:10PM	EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications (GlobeNewswire)
07:00AM	Libtayo (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation (GlobeNewswire)
Nov-18-25 04:45AM	Is Regeneron Pharmaceuticals (REGN) One of the Best Gene-Editing Stocks to Buy According to Hedge Funds? (Insider Monkey)
Nov-17-25 04:22PM	Stock Market Today: Dow Skids, AI Play Dives As Peter Thiel Exits; Netflix Divvies Up Its Shares (Live Coverage) (Investor's Business Daily)
03:02PM	Stock Market Today: Dow Dips As Biotech Eyes Entry; Why Netflix Went From $1,100 To $111 (Live Coverage) (Investor's Business Daily)
Nov-14-25 04:02PM	Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail (Investor's Business Daily)
08:58AM	Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? (Zacks)
Nov-13-25 09:45AM	Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls (The Fly)
07:00AM	Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs (GlobeNewswire)
05:15AM	Here Are the Top Growth Healthcare Stocks Every New Investor Should Know (Motley Fool)
Nov-12-25 07:49PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
12:26PM	Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains (Zacks)
Nov-10-25 04:20PM	Merck's Heart Pill Slashes Cholesterol Levels in Test Patients (Barrons.com)
06:56AM	Dupixent set for ninth US approval after Phase III AFRS success (Clinical Trials Arena)
04:25AM	Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks (StockStory)
Nov-08-25 02:32PM	Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% (Investor's Business Daily)
10:46AM	Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet (GlobeNewswire)
Nov-07-25 05:09PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
09:56AM	Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble (Zacks)
08:00AM	Dupixent (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review (GlobeNewswire)
Nov-05-25 10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
Nov-04-25 11:31PM	Michael Burry Is Super-Bearish On Palantir With 5 Million Puts (Benzinga)
12:38AM	5 Revealing Analyst Questions From Regeneron's Q3 Earnings Call (StockStory)
Nov-03-25 04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
07:58AM	2 Beaten-Down Stocks That Could Be About to Rally (Motley Fool)
Oct-31-25 09:33AM	Sometimes the only winning move is not to play, says Michael Burry in bubble warning (MarketWatch)
08:37AM	AstraZenecas gMG drug fails to fend off rivals despite Phase III win (Clinical Trials Arena)
07:00AM	Dupixent (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award (GlobeNewswire)
Oct-30-25 07:14PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
Oct-29-25 03:29PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
12:11PM	Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher? (Barrons.com)
08:49AM	FDA rejects Regenerons pre-filled Eylea HD syringes amid filling facility woes (Pharmaceutical Technology)
01:32AM	REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage (StockStory)
12:03AM	Market Wrap: Top Stock Movers- PayPal, Nokia, and Wayfair (TheStreet)
Oct-28-25 03:03PM	REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase (Zacks) +11.82%
12:11PM	Why Are Regeneron (REGN) Shares Soaring Today (StockStory)
12:10PM	Nvidia investing $1B in Nokia, Trump admin. inks nuclear deal (Yahoo Finance Video)
09:30AM	Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics (Zacks)
09:01AM	Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts (Investor's Business Daily)
07:58AM	Regeneron (NASDAQ:REGN) Surprises With Strong Q3 (StockStory)
07:40AM	Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
07:06AM	Regeneron earnings beat estimates amid strong anti-inflammatory drug demand (Investing.com)
06:40AM	Regeneron: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Regeneron Reports Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
Oct-26-25 11:13PM	Regeneron Earnings: What To Look For From REGN (StockStory)
07:25AM	European Medicines Agency Adopts a Positive Opinion on ?Regeneron's (REGN) Libtayo (Insider Monkey)
Oct-24-25 07:03PM	Analyst Report: Sanofi (Morningstar Research)
04:12PM	Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue (Investor's Business Daily)
03:19PM	Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week (The Wall Street Journal)
01:14PM	Long Leaf Partners Fund's Comment on Regeneron (REGN) (Insider Monkey)
10:01AM	Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline (Zacks)
09:56AM	REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline? (Zacks)
02:55AM	Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance (The Wall Street Journal)
Oct-23-25 09:15AM	Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS (Zacks)
09:05AM	RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised (Zacks)
Oct-21-25 10:00AM	Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline (Zacks)
Oct-20-25 09:25AM	Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition? (Zacks)
Oct-17-25 04:21PM	The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. (Investor's Business Daily)
07:30AM	Libtayo (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation (GlobeNewswire)
Oct-16-25 02:54AM	REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised) (Zacks)
Oct-15-25 09:11AM	Next-Generation Targeted Therapies Reshape Precision Oncology Landscape (PR Newswire)
07:00AM	Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers (GlobeNewswire)
Oct-14-25 10:49AM	Regenerons Q3 2025 Earnings: What to Expect (Barchart)
10:00AM	2 Stocks Down 17% and 21% to Buy Right Now (Motley Fool)
Oct-13-25 10:02AM	REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Zacks)
09:44AM	Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge (Insider Monkey)
09:41AM	Stock Market Today: Dow Jumps 400 Points On Trump Tariff Comments; Broadcom, Nvidia, Tesla Rally (Live Coverage) (Investor's Business Daily)
Oct-12-25 10:18AM	DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss (GlobeNewswire)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LAROSA JOSEPH J	EVP General Counsel and Secret	Nov 20 '25	Option Exercise	555.67	14,450	8,029,431	35,525	Nov 24 04:07 PM
Bassler Bonnie L	Director	Nov 20 '25	Option Exercise	371.40	760	282,264	2,308	Nov 24 04:05 PM
Bassler Bonnie L	Director	Nov 20 '25	Sale	750.00	760	570,000	1,548	Nov 24 04:05 PM
Bassler Bonnie L	Director	Nov 20 '25	Proposed Sale	750.00	760	570,000		Nov 20 02:31 PM
Pitofsky Jason	VP Controller	Nov 07 '25	Sale	651.43	431	280,766	4,233	Nov 10 04:37 PM
Jason Pitofsky	Officer	Nov 07 '25	Proposed Sale	651.00	431	280,581		Nov 07 05:06 PM
POON CHRISTINE A	Director	Oct 29 '25	Option Exercise	520.01	6,500	3,380,065	8,852	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 30 '25	Option Exercise	520.01	2,712	1,410,267	5,064	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 29 '25	Sale	654.27	6,500	4,252,745	2,352	Oct 31 04:09 PM
MURPHY ANDREW J	EVP Research	Oct 29 '25	Option Exercise	555.67	35,000	19,448,450	84,074	Oct 31 04:06 PM
Christine Poon	Director	Oct 29 '25	Proposed Sale	652.91	6,500	4,243,915		Oct 29 04:36 PM
SING GEORGE L	Director	Dec 31 '24	Option Exercise	413.33	3,338	1,379,696	29,610	Jan 03 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Cyber Swan Sale

50% Off Elite

REGN

Regeneron Pharmaceuticals, Inc

Upgrade your FINVIZ experience